Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D473/00—Heterocyclic compounds containing purine ring systems
  • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
  • C07D473/32—Nitrogen atom
  • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K31/52—Purines, e.g. adenine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/02—Nasal agents, e.g. decongestants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/08—Bronchodilators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/16—Central respiratory analeptics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/04—Antipruritics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/14—Decongestants or antiallergics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/06—Antianaemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
  • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
  • C07D239/72—Quinazolines; Hydrogenated quinazolines
  • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
  • C07D239/88—Oxygen atoms
  • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D473/00—Heterocyclic compounds containing purine ring systems
  • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
  • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems

Definitions

• the present invention is directed to a method of preparing compounds such as 3-phenyl-2- [ (9H-purin-6-ylamino) -methyl] -3H-quinazolin-4-one (i.e., the compound of structural formula (I)), and compounds structurally related to (I) .
• Selective inhibitors of PI3K ⁇ possess the advantage of enabling the skilled artisan to inhibit the ⁇ isoform in an in vi tro or in vivo system, while leaving the other PI3K isoforms substantially unaffected.
• Such utility can have important, consequences in treating diseases or conditions that are mediated by PI3K ⁇ , inasmuch as at therapeutic concentrations a selective PI3K ⁇ inhibitor can avoid undesirable side effects or tox- icities that would be associated with inhibition of the ⁇ , ⁇ , and ⁇ isoforms of PI3K.
• the present invention relates to a method of preparing a compound such as 3-phenyl-2- [ (9H- purin-6-ylamino) -methyl] -3H-quinazolin-4-one and compound structurally related thereto.
• the present invention relates to a method preparing a compound of structural formula (I) , and substituted and related compounds, for example, compounds of structural formulae (II) and (III) .
• the present invention is directed to a new and facile synthesis of compounds (I) , (II) , and (III) , which are inhibitors of pllO ⁇ .
• the method disclosed herein is a new arid economical synthesis of these and other compounds and is particularly valuable in that it allows the.
• one aspect of the present invention is to provide a method of synthesizing compounds capable of inhibiting the biological activity of human PI3K ⁇ , in particular compounds that inhibit Pl3K ⁇ selectively compared to the other PI3K iso- forms.
• Another aspect of the present invention is to provide a method of synthesizing a compound of structural formula (I) :
• Still another aspect of the present invention is to provide a method of synthesizing com- pounds structurally related to compound (I) , for example, compounds having a structural formula (II) :
• X and Y, independently, are N or CR C ;
• Z is selected from the group consisting of NR 7 , 0, and CR ⁇ R 11 , wherein R 10 and R 11 , independently, are hydrogen or C ⁇ _ 3 alkyl;
• R 1 independently, are hydrogen, halo, or C ⁇ - 3 alkyl ;
• R 2 and R 3 independently, are hydrogen, halo, or C ⁇ _ 3 alkyl;
• R 6 is hydrogen, halo, or NR a R b ;
• R 7 is hydrogen or R 5 and R 7 are taken together with the atoms to which they are attached to form a five- or six-membered saturated ring;
• R 8 is C 1-3 alkyl, halo, CF 3 , or CH 2 C 3 - 6 hetero- cycloalkyl;
• n is 0, 1, or 2;
• R a is hydrogen, C ⁇ - 4 alkyl, or CH 2 C 6 H 5 ;
• R b is hydrogen or C ⁇ _ 3 alkyl;
• R c is hydrogen, C ⁇ _ 3 alkyl, or halo.
• Another aspect of the present invention is to provide a method of synthesizing the S- or the R- enantiomer of a compound of structural formula (II) when R 5 is different from hydrogen.
• the method provides an increased stereochemical yield of the desired S- or R-enantiomer, e.g., the S-enantiomer having a structural formula (Ila) :
• Yet another aspect of the present invention is to provide a method of preparing compounds structurally related to compound (I) , for example, a compound having a structural formula (III) :
• B is an optionally substituted monocyclic or bicyclic ring system containing at least two nitrogen atoms, and at least one ring of the system is aromatic;
• R , R , R , and n are as defined above; * indicates a chiral center; and PG is hydrogen or a protecting group, comprising a step of subjecting the compound to reducing conditions to form a compound having a structure
• Yet another aspect of the present invention is to provide a method of cyclizing and preserving the chirality of a compound having a structure
• R 5 , R 8 , R 9 , *, PG, and n are as defined above;
• A is NH 2 , protected NH 2 , or N 3 , comprising a step of deprotecting the protected NH 2 group to provide an NH 2 group or converting the N 3 group to provide an NH 2 group, followed by cyclizing the resulting intermediate compound under acidic or basic conditions to form a compound having a structure
• compounds of structural formulae (II) and (III) also can be made by the above and modified procedures.
• compounds disclosed in U.S. Patent No. 6,667,300, incorporated herein by reference also can be prepared by the methods set forth herein.
• chiral compounds of structural formulae (II) and (III), and chiral compounds disclosed in U.S. Patent No. 6,667,300 can be prepared in high stereochem- ical purity.
• Another aspect of the present invention is to provide a method of preparing compounds related to the compound of structural formula (I) , such as, for example, compounds of structural formulae (II) and (III), and, related compounds, such as the compounds disclosed in U.S. Patent Nos .
• the present invention is directed to an efficient synthesis of 3-phenyl-2- [ (9H-purin-6-yl- amino) -methyl] -3H-quinazolin-4-one (i.e., compound (I) ) .
• the present invention also is directed to methods of synthesizing compounds related in structure to compound (I) , including substituted compounds of structural formula (I) , for example, compounds having a structural formula (II) or (III) , and particularly a desired S- or R-enantiomer of chiral compounds of structural formulae (II) and (III) (e.g., compounds of structural formula (II) wherein R 5 is different from hydrogen) in a high stereochemical yield: wherein X and Y, independently, are N or CR C ; Z is selected from the group consisting of NR 7 , O, and CR ⁇ R 11 , wherein R 10 and R 11 , independently, are hydrogen or C_ 3 alkyl; R 1 , independently, are hydrogen, halo
• R 5 is C ⁇ _ 3 alkyl, CH 2 CF 3 , phenyl, CH 2 C ⁇ CH, C !
• R 6 is hydrogen, halo, or NR a R b
• R 7 is hydrogen or R 5 and R 7 are taken together with the atoms to which they are attached to form a five- or six-membered saturated ring
• R 8 is C ⁇ - 3 alkyl , halo , CF 3 , or CH 2 C 3 - 6 hetero- cyclo lkyl
• n is 0 , 1 , or 2
• R a is hydrogen, C 1 _ alkyl, or CH 2 C 6 H 5
• R b is hydrogen or C ⁇ - 3 alkyl
• R c is hydrogen, C ⁇ _ 3 alkyl, or halo.
• the present disclosure first illustrates a synthetic route to provide simple, unsubstituted compound (I) .
• using properly substituted starting materials and reagents of desired stereochemistry yields compounds of structural formulae (II) and (III) , stereoselec- tively and in good yield, using an identical or similar synthetic route.
• the following benzoic acid (a) , aniline (b) , purine compound (c) , and carboxyl- ic acid (d) can be utilized in the present methods.
• alkyl is defined as straight chained and branched hydrocarbon groups containing the indicated number of carbon atoms, e.g., methyl, ethyl, and straight chain and branched propyl and butyl groups .
• C ⁇ - 3 alkylene and “C 1 _ 4 alkylene” are defined as hydrocarbon groups containing the indicated number of carbon atoms and one less hydrogen than the corresponding alkyl group.
• C 2 - S alkenyl and “C 2 _ 6 alkynyl” are defined as a hydrocarbon group containing the indicated number of carbon atoms and a carbon-carbon double bond or a carbon-carbon triple bond, respec- tively.
• C 3-6 cycloalkyl and “C 3 _ 6 cyclo- alkenyl” are defined as a cyclic hydrocarbon group containing the indicated number of carbon atoms .
• the C 3 _ 6 cycloalkenyl group contains a carbon-carbon double bond in the ring.
• C 3 _ 6 heterocycloalkyl is defined similarly as cycloalkyl except the ring contains one or two heteroatoms selected from the group consisting of O, NR d , and S.
• aryl, " alone or in combination, is defined herein as a monocyclic or polycyclic aromatic group, preferably a monocyclic or bicyclic aromatic group, e.g., phenyl or naphthyl .
• an "aryl” group can be unsub- stituted or substituted, for example, with one or more, and in particular one to three, halo, alkyl, phenyl, hydroxyalkyl, alkoxy, alkoxyalkyl, halo- alkyl, nitro, amino, alkylamino, acylamino, alkyl- thio, alkylsulfinyl, and alkylsulfonyl .
• aryl groups include phenyl, naphthyl, biphenyl, tetrahydronaphthyl , chlorophenyl, fluorophenyl, aminophenyl, methylphenyl, methoxyphenyl, trifluoro- methylphenyl, nitrophenyl, carboxyphenyl , and the like.
• heteroaryl is defined herein as a monocyclic or bicyclic ring system containing one or two aromatic rings and containing at least one nitrogen, oxygen, or sulfur atom in an aromatic ring, and which can be unsubstituted or substituted, .
• substituents like halo, alkyl, hydroxyl, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkyl, nitro, amino, alkylamino, acylamino, alkythio, alkylsul- finyl, and alkylsulfonyl .
• heteroaryl groups include thienyl, furyl, pyridyl, oxazolyl, quinolyl, isoquinolyl, indolyl, triazolyl, iso- thiazolyl, isoxazolyl, imidizolyl, benzothiazolyl, pyrazinyl, pyrimidinyl, thiazolyl, and thiadiazolyl .
• halo is defined as fluoro, bromo, chloro, and iodo.
• hydroxy 3 is defined as -OH.
• alkoxy is defined as -OR, wherein R is alkyl.
• alkoxyalkyl is defined as an alkyl group wherein a hydrogen has been replaced by an alkoxy group.
• (alkylthio) alkyl is defined similarly as alkoxyalkyl, except a sulfur atom, rather than an oxygen atoms, is present.
• hydroxyalkyl is defined as a hydroxyl group appended to an alkyl group.
• amino is defined as -NH 2
• alkylamino is defined as -NR 2 , wherein at least one R is alkyl and the second R is alkyl or hydrogen.
• alkylthio is defined as -SR, wherein R is alkyl.
• alkylsulfinyl is defined as R-S0 2 , wherein R is alkyl.
• alkylsulfonyl is defined as
• R-S0 3 wherein R is alkyl.
• nitro is defined as -N 2 .
• trifluoromethyl is defined as -CF,
• trifluoromethoxy is defined as -OCF 3
• cyano is defined as -CN.
• R 1 is hydrogen, fluoro, chloro, methyl, or
• R 2 is hydrogen, methyl, chloro, or fluoro
• R 3 is hydrogen or fluoro
• R 6 is NH 2 , hydrogen, or fluoro
• R 7 is hydrogen or R 5 and R 7 are taken together to form
• R 8 is methyl, trifluoromethyl, chloro, or fluoro;
• R c is hydrogen, methyl, fluoro, or bromo; and n is 0 or 1. .
• Y is selected from the group consisting of null, S, O, and NH.
• the B ring can be monocyclic or bicyclic. Monocyclic B ring systems are aromatic. Bicyclic B ring systems contain at least one aromatic ring, but both rings can be aromatic.
• a ring systems include, but are not limited to, imidazolyl, pyrazolyl, 1, 2, 3-triazolyl, pyridizinyl, pyrimidin- yl, pyrazinyl, 1, 3 , 5-triazinyl, purinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8- naphthyridinyl , pteridinyl, lH-indazolyl, and benzimidazolyl .
• One starting material for the present synthetic route to compound (I) is an o-nitro-substi- tuted benzoic acid (1) .
• the benzoic acid (1) optionally is converted to the corresponding acid chloride using a reagent well known in the art, e.g., oxalyl chloride or thionyl chloride in the presence of a catalytic amount of DMF in an organic solvent, such as CH 2 C1 2 or THF.
• the acid chloride then is reacted with an aniline, in the presence of a base, to form an N- phenyl-benzamide (2) .
• N-phenyl-benzamide (2) is reacted with thionyl chloride or a similar reagent known to persons skilled in the art, either neat or in a solvent and in the presence of optional catalytic amount of DMF, to provide the corresponding N-chloro compound, followed by the addition of an N-protected 2-amino substituted carboxylic acid, e.g., N-BOC-2-amino- acetic acid and a base in an organic or aqueous solvent, to yield a carbamic acid ester derivative (3).
• a desired S-enantiomer of compound (II), i.e., a compound (Ila), is pro- vided in high stereochemical yield.
• the carbamic acid ester derivative (3) then is subjected to reducing conditions, such as zinc metal dust and acetic acid, tin (II) chloride, iron, or catalytic hydrogenation in the presence of a palladium, platinum, rhodium, or nickel catalyst, to form the cyclized carbamic acid ester (4) .
• the cyclized carbamic acid ester (4) then is treated under conditions that remove the BOC protecting group from the amino group, e.g., trifluroacetic acid or hydrogen chloride, to provide a 2- (1-amino- methyl) -3-phenyl-3H-quinazolin-4-one (5).
• the quinozolin-4-one (5) then is reacted with 6-bromo- purine in the presence of a base in a solvent, e.g., ethanol, n-butanol, t-butanol, or THF, at 60°C to 120°C for 8 to 36 hours, to provide the 3-phenyl-2- [ (9H-purin-6-ylamino) -methyl] -3H-quinazolin-4-one
• a solvent e.g., ethanol, n-butanol, t-butanol, or THF
• the method provides a desired S- or R-enantiomer of a compound (II) when R 5 is different from hydrogen.
• the desired enantiomer of a chiral compound (III) also can be provided in high stereochemical yield.
• a chiral compound (II) or (III) can be prepared in at least 95% stereochemical purity, typically at least 97% stereochemical purity, and more typically at least 98% stereochemical purity.
• the stereochemical purity of the desired S- or R-enantiomer is at least 99%, and often greater than 99%.
• all starting materials and reagents were obtained from commercial suppliers and used without further purification.
• the syrup was dissolved in dry dioxane (80 mL) and slowly added to a suspension of aniline (49 mL, 0.54 mol, 1 eq) and NaHC0 3 (90 g, 1.08 mol, 2 eq) in a mixture of dioxane (250 mL) and H 2 0 (250 mL) at 6°C. The temperature reached 27°C at the end of the addition. After 30 min, the reaction mixture was treated with H 2 0 (1.2 L) .
• the syrup was dissolved in toluene (200 mL) and purified by flash chromatography on a silica gel plug (13 x 15 cm, 2 L dry silica) eluted with hexanes/EtOAc (10%, 4 L; 15%, 4 L; 17.5%, 8 L; 25%, 4 L) to yield the product as an off-white foamy solid (33.6 g, 69%).
• the reaction mixture was stirred for 1 h, concentrated in vacuo, and partitioned between CH 2 C1 2 (150 mL) and 10% K 2 C0 3 (sufficient amount to keep the pH greated than 10) .
• the aqueous layer was extracted with additional CH 2 C1 2 (100 mL) , and the combined organic layers were washed with H 2 0 (50 mL) and brine (50 mL) . After drying with MgS0 , the solution was concentrated to an off-white solid (22 g, 88%) .
• Additional compounds related to compound (7) can be prepared using the present general synthetic method by a proper selection of appropriate starting materials and reagents, and by scaling all reagent amounts proportionately based on the amount of starting material used.
• Specific nonlimiting examples of compounds prepared by the method of the invention are provided below. It is understood in the art that protecting groups can be employed where necessary in accordance with general principles of synthetic chemistry. These protecting groups are removed in the final steps of the synthesis under basic, acidic, or hydrogenolytic conditions well known to persons skilled in the art.
• synthesis of compounds related to compounds of structural formulae (II) and (III) can be accomplished using the synthetic scheme set forth herein.
• 6-nitro-benzamide Following the procedure for Compound (7) substituting 2-nitro-5-methylbenzoic acid for 2- fluoro-6-nitrobenzoic acid and 2 , 6-difluoroaniline for aniline.
• Step B L- ⁇ 2- [ (2, 6-Difluoro-phenyl) - (2- methyl-6-nitro-benzoyl) -amino] -1-methyl-2-oxo- ethyl ⁇ -carbamic acid tert-butyl ester.
• B is an optionally substituted monocyclic or bicyclic ring system containing at least two nitrogen atoms, and at least one ring of the system is aromatic;
• C is selected from the group consisting of
• R 8 is selected from the group consisting of
• R d is selected from the group consisting of hydrogen, C ⁇ _ 6 alkyl, heteroC ⁇ _ 3 alkyl, C ⁇ _ 3 alkylenehet- eroC ⁇ - 3 alkyl, arylheteroC !
• A is N0 2 , a protected NH 2 group, N 3 , or NH 2 .
• the group is a "protected" amino group, i.e., a surrogate amino group. This is demonstrated in the above synthetic sequences wherein the N0 2 group is converted to an amino group via a reduction step.
• A is a protected NH 2 group or N 3
• an NH 2 group can be provided by deprotecting a pro- tected NH 2 group or by converting an N 3 group to an NH 2 group by conversion procedures well known in the art.
• an unprotected NH 2 group also can be the A group, as long as the NH 2 group is available for cyclization in a subsequent step. See, for example, J " . Chem. Soc. (1956), page 985.
• a starting material for the synthesis of a compound (II) or (III) can be the substituted benzoic acid (lb) (lb)
• Amide compound (2b) then is converted to an intermediate imidoyl halide.
• the halide can be a chloride, bromide, or iodide.
• Amide compound (2b) can be converted to an intermediate imidoyl halide, preferably an imidoyl chloride, by procedures known in the art.
• amide compound (2b) can be converted to an intermediate imidoyl halide by reaction of amide (2b) with a chlorinating, brominat- ing, or iodinating agent, e.g., S0C1 2 , PPh 3 Cl 2 , a complex of PPh 3 and Cl 2 obtained in si tu, a mixture of PPh 3 and CC1 4 , PC1 5 , P0C1 3 , (C0C1) 2 , phosgene, diphosgene, triphosgene, or a corresponding and stable bromo or iodo compound, in the absence or presence of base, such as triethylamine, and either neat, such as with S0C1 2 or POCl 3 , or in a solvent.
• a chlorinating, brominat- ing, or iodinating agent e.g., S0C1 2 , PPh 3 Cl 2 , a complex of PPh 3 and Cl 2
• the intermediate imidoyl halogenide also can be formed in a one-pot reaction from a compound (lb) and amine R 9 NH 2 by using an excess amount of chlorinating agent, such as a mixture of PPh 3 and CC1 4 .
• the imidoyl halogenide intermediate also can be formed by halogenation of an imine, such as a Schiff base
• intermediate compounds having a facile leaving group other than halogen also can be used in place of an imidoyl halogenide.
• an imidoyl triflate formed in si tu from triflie anhydride and an amide (2b) can be used.
• the intermediate imidoyl halogenide or triflate After generation of the intermediate imidoyl halogenide or triflate, the intermediate is reacted with a carboxylic acid (PG-DH-C-C0 2 H) and base, or a salt of a carboxylic acid, in an organic solvent, water, or mixture thereof to form a com- pound (3b) .
• PG-DH-C-C0 2 H carboxylic acid
• base or a salt of a carboxylic acid
• compound (3b) is cyclized (i) by reduction of group A, if A is N0 2 , or (ii) by deprotecting or converting group A to NH 2 , if A is protected amino or N 3 , respectively, to provide the following compound
• the reduction reaction can be performed, for example, by reduction with tin (II) chloride in aq. HCI or organic solvent such as DMF, reduction with Fe or Zn with HOAc, HCI, NH 4 C1, reduction with hydrogen over a metal catalyst such as palladium, platinum, rhodium, or nickel, reduction with hydrogen in si tu, for example, Pd with formic acid or its salt in an alcohol solution, reduction of an o- nitrobenzoylimide with CO, base, and selenium (Tetr.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Immunology (AREA)
• Diabetes (AREA)
• Pulmonology (AREA)
• Physical Education & Sports Medicine (AREA)
• Oncology (AREA)
• Rheumatology (AREA)
• Hematology (AREA)
• Endocrinology (AREA)
• Biomedical Technology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Pain & Pain Management (AREA)
• Dermatology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Ophthalmology & Optometry (AREA)
• Communicable Diseases (AREA)
• Urology & Nephrology (AREA)
• Epidemiology (AREA)
• Vascular Medicine (AREA)
• Heart & Thoracic Surgery (AREA)
• Transplantation (AREA)
• Otolaryngology (AREA)
• Gastroenterology & Hepatology (AREA)
• Biochemistry (AREA)
• Cardiology (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=34969603

Family Applications (2)

Family Applications After (1)

Country Status (23)

Cited By (149)

Families Citing this family (275)

Family Cites Families (114)

• 2005
  • 2005-05-12 PL PL05752122T patent/PL1761540T3/pl unknown
  • 2005-05-12 CN CN2011101010187A patent/CN102229609A/zh active Pending
  • 2005-05-12 DK DK13150110.8T patent/DK2612862T3/en active
  • 2005-05-12 EP EP13150110.8A patent/EP2612862B1/en not_active Expired - Lifetime
  • 2005-05-12 RS RS20161180A patent/RS55551B1/sr unknown
  • 2005-05-12 CA CA2566609A patent/CA2566609C/en not_active Expired - Lifetime
  • 2005-05-12 EP EP05752122.1A patent/EP1761540B1/en not_active Expired - Lifetime
  • 2005-05-12 ES ES13150110.8T patent/ES2605792T3/es not_active Expired - Lifetime
  • 2005-05-12 AU AU2005245875A patent/AU2005245875C1/en active Active
  • 2005-05-12 PT PT57521221T patent/PT1761540T/pt unknown
  • 2005-05-12 DK DK05752122.1T patent/DK1761540T3/en active
  • 2005-05-12 LT LTEP05752122.1T patent/LT1761540T/lt unknown
  • 2005-05-12 US US11/596,092 patent/US7932260B2/en not_active Ceased
  • 2005-05-12 PT PT131501108T patent/PT2612862T/pt unknown
  • 2005-05-12 HR HRP20161751TT patent/HRP20161751T1/hr unknown
  • 2005-05-12 ES ES05752122.1T patent/ES2607804T3/es not_active Expired - Lifetime
  • 2005-05-12 ME MEP-2016-297A patent/ME02688B/me unknown
  • 2005-05-12 HU HUE13150110A patent/HUE030950T2/en unknown
  • 2005-05-12 EP EP21169213.2A patent/EP3943494A1/en not_active Withdrawn
  • 2005-05-12 RS RS20161005A patent/RS55546B1/sr unknown
  • 2005-05-12 PL PL13150110T patent/PL2612862T3/pl unknown
  • 2005-05-12 WO PCT/US2005/016661 patent/WO2005113554A2/en not_active Ceased
  • 2005-05-12 SI SI200532295T patent/SI3153514T1/sl unknown
  • 2005-05-12 PT PT161852132T patent/PT3153514T/pt unknown
  • 2005-05-12 EP EP16185213.2A patent/EP3153514B1/en not_active Expired - Lifetime
  • 2005-05-12 US US13/730,256 patent/USRE44638E1/en not_active Expired - Lifetime
  • 2005-05-12 PL PL16185213T patent/PL3153514T3/pl unknown
  • 2005-05-12 JP JP2007513402A patent/JP2007537291A/ja active Pending
  • 2005-05-12 WO PCT/US2005/016778 patent/WO2005113556A1/en not_active Ceased
  • 2005-05-12 LT LTEP13150110.8T patent/LT2612862T/lt unknown
  • 2005-05-12 HU HUE05752122A patent/HUE030839T2/en unknown
  • 2005-05-12 ES ES16185213T patent/ES2873875T3/es not_active Expired - Lifetime
  • 2005-05-12 ME MEP-2016-284A patent/ME02695B/me unknown
  • 2005-05-12 SI SI200532115A patent/SI2612862T1/sl unknown
  • 2005-05-12 CN CN2005800234499A patent/CN101031569B/zh not_active Expired - Lifetime
• 2006
  • 2006-11-09 IL IL179176A patent/IL179176A/en active IP Right Grant
• 2009
  • 2009-10-23 AU AU2009230739A patent/AU2009230739A1/en not_active Abandoned
• 2010
  • 2010-03-25 US US12/732,124 patent/US20100256167A1/en not_active Abandoned
  • 2010-03-25 US US12/732,128 patent/US8207153B2/en not_active Expired - Lifetime
• 2011
  • 2011-06-17 US US13/163,597 patent/US20120015964A1/en not_active Abandoned
• 2012
  • 2012-12-27 US US13/728,807 patent/US8586597B2/en not_active Expired - Fee Related
  • 2012-12-28 US US13/730,276 patent/USRE44599E1/en not_active Expired - Lifetime
• 2013
  • 2013-02-12 US US13/765,610 patent/US8779131B2/en not_active Expired - Lifetime
  • 2013-10-08 US US14/049,154 patent/US8993583B2/en not_active Expired - Lifetime
  • 2013-10-08 US US14/049,163 patent/US8980901B2/en not_active Expired - Lifetime
• 2014
  • 2014-05-21 US US14/284,331 patent/US9149477B2/en not_active Expired - Lifetime
• 2015
  • 2015-08-13 US US14/826,096 patent/US10336756B2/en not_active Expired - Lifetime
  • 2015-09-20 IL IL24173215A patent/IL241732B/en active IP Right Grant
• 2016
  • 2016-11-24 CY CY2016046C patent/CY2016046I1/el unknown
  • 2016-12-06 HR HRP20161657TT patent/HRP20161657T1/hr unknown
  • 2016-12-14 CY CY20161101299T patent/CY1118493T1/el unknown
  • 2016-12-28 CY CY20161101359T patent/CY1118516T1/el unknown
• 2017
  • 2017-02-16 BE BE2017C002C patent/BE2017C002I2/fr unknown
  • 2017-02-17 LU LU00005C patent/LUC00005I2/en unknown
  • 2017-02-22 HU HUS1700006C patent/HUS1700006I1/hu unknown
  • 2017-02-23 LT LTPA2017004C patent/LTC1761540I2/lt unknown
  • 2017-03-10 FR FR17C1007C patent/FR17C1007I2/fr active Active
  • 2017-03-24 NL NL300867C patent/NL300867I2/nl unknown
• 2019
  • 2019-05-21 US US16/418,558 patent/US10906907B2/en not_active Expired - Lifetime
  • 2019-10-15 IL IL269976A patent/IL269976B/en active IP Right Grant
• 2020
  • 2020-11-24 US US17/103,631 patent/US20210332047A1/en not_active Abandoned
• 2021
  • 2021-03-31 IL IL281945A patent/IL281945A/en unknown